Bound Therapeutics
Bound Therapeutics is a biotechnology company developing RNA-based therapies for rare and hard-to-treat diseases, with a focus on oncology. Their proprietary platform, Magic Bullet Designer (MBD), uses advanced AI and machine learning for tissue-specific delivery of RNA therapeutics to enhance precision and efficacy. The company is in the preclinical stage with pipeline treatments for aggressive malignancies and genetic disorders. They have demonstrated in vivo proof-of-concept efficacy and safety in an aggressive breast cancer mouse model with their lead molecule BND6482, targeting microRNA-21. Their business model involves commercializing lead compounds for specific cancers and expanding into other therapeutic markets like lung cancer, cardiovascular disease, and diabetes through alliances with pharmaceutical companies. Their exit strategy is acquisition by a pharmaceutical firm.
Bound Therapeutics
Bound Therapeutics is a biotechnology company developing RNA-based therapies for rare and hard-to-treat diseases, with a focus on oncology. Their proprietary platform, Magic Bullet Designer (MBD), uses advanced AI and machine learning for tissue-specific delivery of RNA therapeutics to enhance precision and efficacy. The company is in the preclinical stage with pipeline treatments for aggressive malignancies and genetic disorders. They have demonstrated in vivo proof-of-concept efficacy and safety in an aggressive breast cancer mouse model with their lead molecule BND6482, targeting microRNA-21. Their business model involves commercializing lead compounds for specific cancers and expanding into other therapeutic markets like lung cancer, cardiovascular disease, and diabetes through alliances with pharmaceutical companies. Their exit strategy is acquisition by a pharmaceutical firm.